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The classical model of cytokine signaling dominates our view of specific gene activation
by cytokines such as the interferons (IFNs). The importance of the model extends beyond
cytokines and applies to hormones such as growth hormone (GH) and insulin, and growth
factors such as epidermal growth factor (EGF) and fibroblast growth factor (FGF). Accord-
ing to this model, ligand activates the cell via interaction with the extracellular domain of
the receptor. This results in activation of receptor or receptor-associated tyrosine kinases,
primarily of the Janus activated kinase (JAK) family, phosphorylation and dimerization of
the signal transducer and activator of transcription (STAT) transcription factors, which dis-
sociate from the receptor cytoplasmic domain and translocate to the nucleus. This view
ascribes no further role to the ligand, JAK kinase, or receptor in either specific gene acti-
vation or the associated epigenetic events. The presence of dimeric STATs in the nucleus
essentially explains it all. Our studies have resulted in the development of a non-canonical,
more complex model of IFNγ signaling that is akin to that of steroid hormone (SH)/steroid
receptor (SR) signaling. We have shown that ligand, receptor, activated JAKs, and STATs
are associated with specific gene activation, where the receptor subunit IFNGR1 functions
as a co-transcription factor and the JAKs are involved in associated epigenetic events. We
found that the type I IFN system functions similarly. The fact that GH receptor, insulin
receptor, EGF receptor, and FGF receptor undergo nuclear translocation upon ligand bind-
ing suggests that they may also function similarly. The SH/SR nature of type I and II IFN
signaling provides insight into the specificity of signaling by members of cytokine fam-
ilies. The non-canonical model could also provide better understanding to more complex
cytokine families such as those of IL-2 and IL-12, whose members often use the same JAKs
and STATs, but also have different functions and properties.
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INTRODUCTION
The classical Janus activated kinase (JAK)/signal transducer and
activator of transcription (STAT) model of cytokine signaling
dominates our view of specific gene activation by cytokines such as
the interferons (IFNs) (1). The importance of the model extends
to complex cytokine families such as those of IL-2 (2) and IL-
12 (3), as well as to hormones such as prolactin and angiotensin
and growth factors such as growth hormone (GH) and platelet-
derived growth factor (4–6). In this model, ligand activates the
cell solely via interaction with the extracellular domain of the
receptor complex (1, 7). This in turn results in the activation of
receptor or receptor-associated tyrosine kinases, primarily of the
JAK family, leading to phosphorylation and dimerization of the
STAT transcription factors, which then dissociate from the recep-
tor cytoplasmic domain and translocate to the nucleus. This view
ascribes no further role to the ligand, JAK kinase, or the receptor
in the signaling process.
It has recently been acknowledged that the classical model of
JAK/STAT signaling was over-simplified in its original form. In the
case of IFNγ, complexity beyond simple JAK/STAT activation is
indicated in the relatively recent demonstration that other path-
ways, including mitogen activated protein kinase (MAPK), phos-
phoinositide 3-kinase (PI3K), Ca2+/calmodulin (CaM) kinase II,
nuclear factor-κB (NF-κB), and others cooperate with or act in
parallel to that of JAK/STAT signaling to regulate IFNγ effects at
the level of gene activation and cell phenotypes (7). All of the
pathways are generic in the sense that a plethora of cytokines, hor-
mones, and growth factors with functions different from those of
IFNγ also activate them.
There is evidence that JAK kinases, including the mutant
JAK2V617F, play an important role in the epigenetics of gene
activation in addition to STAT activation in the cytoplasm (8).
Leukemic cells with a JAK2V617F gain-of-function mutation have
constitutively active JAK2V617F in the nucleus. This leads to phos-
phorylation of tyrosine 41 (Y41) on histone H3, which results in
dissociation of heterochromatin protein 1α (HP1α). The resul-
tant heterochromatin remodeling was associated with exposure of
euchromatin for gene activation. Although present in the nucleus,
wild-type JAK2 was only activated when K562 cells were treated
with PDGF or LIF, or when BaF3 cells were treated with IL-3. The
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question of how a ligand/receptor interaction resulted in the pres-
ence of activated JAK2, pJAK2, in the nucleus was not addressed,
nor its targeting mechanism to discrete genomic sites and specific
promoters.
Signal transducer and activator of transcriptions form dimers
when activated, but there are only seven different types of STATs,
and the dimers are predominantly homomeric in nature. Given
that there are functionally over 60 different types of ligands that
use STATs, it is difficult to decipher the mechanism of their dif-
ferent specificities solely in the context of the particular STATs
involved (9–11). Further, some ligands such as IFNγ and IL-
10 use STAT1α, while other factors such as GH, IL-2, and IL-7
use STAT5β, but these molecules have different effects on cells
(9, 12). The classical model in effect gives the STAT some sort
of Lamarchian power where it “knows” the ligand responsible
for its activation and proceeds on its own to activate specific
genes as well as directing specific epigenetic events associated
with the gene activation. Thus, the classical JAK/STAT model
tells us very little about the unique aspects of IFNγ signaling or
the basis of type I IFN signaling where up to 20 or more IFNs
all interact with the same heterodimeric receptor complex and
activate the same STAT transcription factors, but vary in func-
tions such as antiproliferative activity and apoptosis (10, 11, 13).
Translationally, the lack of understanding of mechanism makes
it very difficult to deal with the mixed effects of type I IFNs as
therapeutics (14).
Focusing initially on IFNγ, we have shown that ligand, recep-
tor, and activated JAKs are involved in nuclear events that are
associated with specific gene activation, where the receptor sub-
unit IFNGR1 functioned as a transcription/co-transcription factor
and the JAKs exerted key epigenetic phosphorylation of histone H3
at tyrosine 41 (H3pY41) (15–17). We showed that the N-terminus
of IFNγ played an important role in extracellular recognition
of receptor, but unexpectedly in the process of endocytosis, the
C-terminus of IFNγ interacted with a specific site in the cyto-
plasmic domain of receptor in the IFNGR1 subunit (18). This
led to development of a mimetic involving the C-terminus of
IFNγ (18). The complex of IFNγ or mimetic with IFNGR1, acti-
vated STAT1α, and activated JAKs 1 and 2 underwent nuclear
translocation for specific gene activation (16). Details of critical
aspects of these studies are provided below. Type I IFNs play a
key role in innate and adaptive immunity with a role in both
antiviral defense and autoimmunity. We have recently shown sim-
ilarities and differences between type I and type II IFN signaling
in terms of IFN/receptor/STAT/JAK complexes in the nucleus and
intracellular receptor interaction.
Peptide mimetics have been increasingly manufactured by the
pharmaceutical industry due to their versatility and high biologi-
cal activity. They offer advantages such as high specificity for their
targets, and low toxicity. Peptides can vary in length from three
to over 60 amino acids, and thus have a broad range of struc-
tural properties. There are already several peptide mimetics on the
market to treat a wide range of diseases, such as boceprevir to treat
hepatitis C, romidepsin as an anti-cancer drug, and liraglutide to
treat Type 2 diabetes (19). The non-canonical model of IFNγ sig-
naling presented here has been key to the development of IFN
mimetics.
CLASSICAL MODEL OF JAK/STAT SIGNALING IN THE
CONTEXT OF IFNγ
The classical model of JAK/STAT signaling for IFNγ is illustrative
of the weight that it puts upon the STATs in specific gene activation
(Figure 1A). The heterodimeric receptor subunits are IFNGR1 and
IFNGR2, respectively (7, 20, 21). An asymmetric dimer of IFNγ
binds predominantly to and cross-links the extracellular domains
of two IFNGR1 chains. The model contends that the cross-linking
initiates allosteric changes in receptor cytoplasmic domains that
are responsible for subsequent events. JAK1 is associated with
IFNGR1, whereas JAK2 is associated with IFNGR2. The extracel-
lular binding of IFNγ to IFNGR1 is somehow responsible for the
movement of JAK2 from IFNGR2 to IFNGR1, where a sequence
of events causes autophosphorylation of the JAKs and tyrosine
phosphorylation of IFNGR1, followed by recruitment and phos-
phorylation of STAT1α (pSTAT1α) at IFNGR1. According to the
model, pSTAT1α forms a dimer, dissociates from IFNGR1 and goes
to the nucleus via an intrinsic nuclear localization sequence (NLS).
FIGURE 1 |The classical and non-canonical models of IFNγ signaling.
(A) In the classical model of IFNγ signaling, dimeric IFNγ cross-links the
IFNGR1 receptor subunit that results in allosteric changes in receptor
cytoplasmic domain. This results in movement of JAK2 from receptor
subunit IFNGR2 to IFNGR1. The JAKs autophosphorylate and then
phosphorylate IFNGR1 cytoplasmic domain. This results in binding,
phosphorylation, and dimer formation of STAT1α. The dimeric STAT1α
dissociates from receptor and undergoes nuclear translocation via an
intrinsic NLS for specific gene activation. (B)The non-canonical model of
IFNγ signaling involves IFNγ binding to receptor extracellular domain,
followed by movement to IFNGR1 cytoplasmic domain in conjunction with
endocytosis. The cytoplasmic binding increases the affinity of JAK2 for
IFNGR1, which is the basis for its movement to IFNGR1. This results in
autoactivation of the JAKs, phosphorylation of IFNGR1 cytoplasmic domain,
and the binding and phosphorylation of STAT1α at IFNGR1. The complex of
IFNGR1/STAT1α/JAK1/JAK2 undergoes active nuclear transport where the
classic polycationic NLS of IFNγ plays a key role for this transport to genes
in the nucleus that are specifically activated by IFNγ. Details of the
non-canonical model are presented in the text. GAS, IFN gamma activated
sequence; H3, histone H3; NPC, Nuclear pore complex.
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Structure studies have shown that dimeric pSTAT1α binds to
the GAS element of the IFNγ promoter (22), which has been inter-
preted as validation of the classical model. There are concerns,
however, with this leap in logic. It has been shown, for example,
that contrary to the requirement of cross-linking of receptor by
IFNγ dimer, monomeric IFNγ can also stimulate the activation of
STAT1α (23, 24). Additionally, the classical JAK/STAT model does
not explain the basis or mechanism for movement of JAK2 from
IFNGR2 to IFNGR1 beyond the interaction of IFNγwith IFNGR1
extracellular domain. Similarly, the recent observations that acti-
vated JAKs undergo nuclear translocation and possess epigenetic
function are not dealt with by the classical model in the context of
the activating ligand (8). The fact that these activated nuclear JAKs
are involved in important epigenetic events is thus disconnected
from the classical model of JAK/STAT signaling by cytokines such
as the IFNs (1, 21). The issues raised above concerning the classical
JAK/STAT model along with the suggestion by the model that the
activated STATs possess the intrinsic property of determining the
specificity of cytokine and other factor signaling is of particular
concern and is dealt with in some detail in the non-canonical sig-
naling model that we have developed, including the development
of IFN mimetics. Rational development of IFN mimetics based on
the classical model, for example, has not been reported based on
cross-linking the receptor extracellular domains. Thus, it is reveal-
ing that little insight concerning such issues is contained within
the classical model of JAK/STAT signaling.
ACTIVATED JAKs IN THE NUCLEUS: ON THEIR OWN OR
TEAM PLAYERS?
At the STAT level, there is recent evidence of a functional inter-
action between different STATs in gene activation/suppression.
Induction of STAT5 phosphorylation by interleukin 2 (IL-2)
resulted in more binding of STAT5 and less binding of STAT3
at similar DNA sites, whereas phosphorylation of STAT3 by IL-6
induced the opposite; the combination of the two STATs resulted
in dynamic regulation of the IL-17 gene locus by the opposing
effects of IL-2 (STAT5) and IL-6 (STAT3) (25, 26). These Yin–
Yang interactions of STAT transcription factors are referred to as
“specification” with respect to lymphocyte phenotypes. How these
STAT interactions at the level of DNA binding translate into spe-
cific gene activation by the inducing cytokine was not obvious.
The recent report of activated JAK2 in the nucleus performing an
epigenetic function is potentially very important for the following
reasons. First, the activated JAK2 was shown to perform the epi-
genetic function of phosphorylation of tyrosine 41 on histone H3
(8). Second, it is highly unlikely that the activated JAK2 is acting
randomly in the nucleus, so how and with what are its epigenetic
functions coordinated?
We will first address aspects of what activated JAKs do in the
nucleus. The epigenetic finding indicated above focused primar-
ily on leukemic cells where a mutated JAK2, JAK2V617F, with a
gain-of-function is found in the nucleus (8). Constitutively active
JAK2V617F was shown to phosphorylate histone H3 on tyro-
sine 41 (H3pY41), which led to dissociation of HP1α from H3.
The resultant heterochromatin remodeling was associated with
exposure of euchromatin for gene activation. Wild-type JAK2 was
shown to be constitutively present in the nucleus of cells also,
but unlike JAK2V617F, was only activated when K562 cells were
treated with the growth factors platelet-derived growth factor or
leukemia inhibitory factor, or when BaF3 cells were treated with
the cytokine IL-3. A key question is whether the nuclear H3 phos-
phorylations are random or under control by factors associated
with the activating cytokine?
This question was addressed in IFN studies by treating cells
with IFNγ and tracking activated JAK2 in the nucleus (16). Using
chromatin immunoprecipitation (ChIP) analysis, it was shown
that activated JAK2 (pJAK2) and H3pY41 were associated with
the GAS promoter element at the IRF-1 gene, a gene that is acti-
vated by IFNγ (16). pJAK1 was also associated with the IRF-1 GAS
element. None of these factors were associated with the promoter
of the β-actin gene, a gene not affected by IFNγ. A similar result
was observed with TYK2 in IFNα treated cells where TYK2 and
H3pY41 were present at the promoter of the oligoadenylate syn-
thetase (OAS) 1 gene, a gene activated by type I IFNs, but not at
the promoter of the β-actin gene (17). It is important to note that
ChIP analysis also showed the presence of STAT1 at the IRF1 and
OAS1 promoters of IFNγ and/or IFNα treated cells, but not at the
β-actin promoter. This would suggest that the activated JAKs and
the STATs track to the same promoters, which would suggest that
their nuclear activities are coordinated.
The above result with JAK2V617F, pJAK2, and H3pY41 is not
the first report of JAKs in the nucleus. For example, JAK1, JAK2,
and TYK2 have all been previously reported to be constitutively
present in the nucleus (27–32). Also, GH has been shown to
induce the translocation of pJAK2 to the nucleus in GH receptor
transfected CHO (27) and CWSV-1 (33) cells. None of these stud-
ies, however, provided the functional significance to an activated
JAK in the nucleus such as that contained in the JAK2 H3pY41
finding (8).
The fact that the hematological disorders associated with
JAK2V617F show characteristic phenotypic similarities would
suggest that the epigenetic activity of JAK2V617F occurs in asso-
ciation with the relevant hematological receptor. It is of inter-
est therefore that it has been shown that JAK2V617F activation
required the association of the mutant JAK2 with a homodimeric
type I cytokine receptor (34, 35). Specifically, erythropoietin recep-
tor, thrombopoietin receptor, or granulocyte colony-stimulating
receptor are required for hormone/growth factor independent
activation of JAK2V617F. This raises the question of whether there
are receptor/JAK2V617F complexes in the vicinity of promoters
of genes that are activated in cancers caused by or associated
with JAK2V617F? All of this has implications for how particular
tyrosine kinases cause or are associated with specific cancers.
Studies in a hematopoietic tumor model in Drosophila with
a hyperactive JAK kinase mutant (Tum-1) of the wild-type
JAK, Hopscotch (Hop), showed a high incidence of hematopoi-
etic tumors (36). Tum-1 caused hyperphosphorylation of the
Drosophila STAT, STAT92E, which was associated with tumor
induction. Reduction in the dose of STAT92E gene had a sup-
pressive effect on Tum-1 tumorigenicity. It was also shown that
the JAK (Tum-1) overactivity globally disrupted heterochromatin
gene silencing and that overexpression of Drosophila HP1 sup-
pressed JAK-induced tumors. Conversely, mutations in the HPI
gene enhanced the Tum-1 oncogenic JAK kinase. These results are
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consistent with and were further clarified by the heterochromatin
destabilization that was caused by the H3Y41-to-H3pY41 effects
of JAK2V617F that resulted in dissociation of HP1α from H3 (8).
A NON-CANONICAL MODEL OF TYPE I AND TYPE II IFN
SIGNALING
Both IFNγ and type I IFNs such as IFNα have been shown to
function intracellularly, activate their respective STATs, and to
translocate to the nucleus of receptor-expressing cells (37, 38).
It was previously shown that IFNγ and one of its receptor sub-
units, IFNGR1, are translocated to the nucleus together with
activated STAT1α (17, 39). Active nuclear transport depended
on a polycationic NLS in the C-terminus of IFNγ, the nuclear
import proteins importins α and β, and ATP/GTP as an energy
source (40, 41).
The nuclear targets of IFNγ and IFNGR1 were also identified
(15, 16). By ChIP followed by PCR, IFNγ, its receptor subunit
IFNGR1, and STAT1α were found to be associated with the IFNγ-
activated sequence (GAS) element in the promoter of two genes
stimulated by IFNγ. Examination of nuclear extracts from IFNγ
treated WISH cells showed that IFNγ, IFNGR1, and STAT1α
proteins were associated with the GAS promoter. The same asso-
ciations were also demonstrated by electrophoretic mobility shift
assay (EMSA). Transfection with a GAS-luciferase gene together
with the IFNGR1 and non-secreted IFNγ resulted in enhanced
promoter activity. Additionally, IFNGR1 fused to the yeast GAL-4
DNA binding domain resulted in enhanced transcription from the
GAL-4 response element in IFNγ treated cells, suggesting the pres-
ence of a transactivation domain in IFNGR1. These nuclear stud-
ies suggest a transcriptional/co-transcriptional role for IFNGR1,
which may provide insight into the specificity of IFNγ signaling. A
model for these non-canonical IFNγ signaling events is presented
in Figure 1B.
Cytokines such as IFNs are assumed to bind solely to the recep-
tor extracellular domain, resulting in allosteric changes on the
cytoplasmic domain that initiates signaling events. It was shown,
however, that IFNγ bound first to IFNGR1 extracellular domain
involving in part its N-terminus and then, during endocytosis,
to IFNGR1 cytoplasmic domain via its C-terminus as described
below and in Figure 2 (41). This was shown as follows. An intra-
cellular excess of a peptide representing the cytoplasmic binding
site on IFNGR1 for the C-terminus of IFNγ, IFNGR1 (253–287),
prevented the complexation of internalized IFNγ with the cyto-
plasmic domain of cell-surface IFNGR1 in cells that were actively
internalizing IFNγ (41). Moreover, such cells were also blocked
with respect to the tyrosine phosphorylation of STAT1α. Thus,
internalized IFNγ appeared to be able to interact with the cyto-
plasmic domain of IFNGR1 in intact cells as part of the signal
transduction events leading to STAT1α tyrosine phosphorylation.
Since the IFNGR1 cytoplasmic domain would be present on the
outer surface of the endocytic vesicle following endocytosis, this
would suggest that IFNγ can traverse the membrane of the endo-
cytic vesicle during internalization to contact the cytoplasmic
domain of IFNGR1. Cytosolic injection of antibodies to IFNγ
C-terminal amino acids 95–132 blocked STAT1α nuclear translo-
cation in response to extracellular IFNγ (40), consistent with these
observations. This further supports the idea that the C-terminus of
FIGURE 2 | IFNγ moves from IFNGR1 extracellular domain to its
cytoplasmic domain during endocytosis. (A) Binding of 125I-IFNγ (10 nM)
to IFNGR on P1388D cells in the presence of unlabeled IFNγ (30 nM) or
IFNGR1(253–287) (1µM) at 4°C for 30 min. The IFNGR1 (253–287) peptide
corresponds to IFNGR1 intracellular binding site for IFNγ. IFNγ but not
IFNGR1 (253–287) blocked extracellular 125I-IFNγ binding. (B) In lane 1,
125I-IFNγ was incubated along with P1388D cells at 4°C for 5 min. In lanes 2
and 3, cells were first incubated with 25 and 50µM, respectively of
IFNGR1(253–287) for 5 min at 37°C to facilitate internalization. Cells were
then washed and incubated alone with 125I-IFNγ (5 nM) at 37°C for 5 min. In
lane 4, cells were incubated alone with 125I-IFNγ at 37°C for 5 min. All of the
cells were then acid washed at 4°C to remove surface 125I-IFNγ, lysed, and
the extracts were immunoprecipitated with antibodies to IFNGR1.
Precipitated IFNGR1 was transferred to nitrocellulose membranes and
electrophoresed. The membranes were subjected to autoradiography and
blotted for IFNGR1 protein. Note that intracellular IFNGR1(253–287) blocked
125I-IFNγ binding to IFNGR1 intracellular domain. (C) Same as for (B), except
extracts were immunoprecipitated with antibodies to STAT1α and blotted
for pTyr701- STAT1α and STAT1α. See Ahmed et al. (41) for details.
endocytosed IFNγ accesses the cytosol, although the mechanism
is as yet undetermined.
As indicated earlier, JAK2 moves from the cytoplasmic domain
of IFNGR2 to IFNGR1 in cells treated with IFNγ via a previously
unknown mechanism. Binding of IFNγ to the 253–287 region of
IFNGR1 was shown to enhance the binding of JAK2 to an adjacent
site on IFNGR1 cytoplasmic domain (42). Thus, the movement of
JAK2 from IFNGR2 to IFNGR1 cytoplasmic domain seems to be
explainable by the exercise of the law of mass action based on
the increased binding affinity of IFNGR1 cytoplasmic domain for
JAK2 (42).
All of the above IFNγ effects can be replicated by peptides
corresponding to the internalized C-terminus residues 95–132
of mouse IFNγ or residues 95–134 of human IFNγ (43). Thus,
peptides corresponding to these residues, mIFNγ(95–132) and
hIFNγ(95–134) respectively, with a palmitate attached for cell pen-
etration, function as IFNγ mimetics. The properties and uses of
these IFNγmimetics are described in detail below. It is noteworthy
that there are no IFN or other cytokine mimetics based on extra-
cellular recognition and cross-linking of receptor chains as per the
classical model.
Recently, insight has been gleaned on the intracellular aspects
of type I IFN signaling. It was shown by western blotting of nuclear
extracts that type I IFN signaling involves activated TYK2 in the
nucleus, similar to pJAK2 in the nucleus of IFNγ treated cells
(17). The nucleus of WISH cells contained constitutively expressed
non-phosphorylated TYK2, but activated TYK2, pTYK2, as well as
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pJAK1 was found in the nucleus of cells only after treatment with
type I IFNs IFNα or IFNτ. Both activated STAT1 and STAT2 were
present in the nucleus of cells treated with type I IFNs. With IFNγ,
only the receptor subunit IFNGR1 underwent nuclear transloca-
tion in IFNγ treated cells, but both receptor subunits IFNAR1 and
IFNAR2 underwent nuclear translocation in type I IFN treated
cells as determined by western blotting of nuclear extracts and con-
focal microscopy of GFP-receptor fusion proteins. The GFP-IFNτ
fusion protein also underwent nuclear import, thus demonstrating
that type I IFNs also translocated to the nucleus.
With all of these components of the type I IFN signaling sys-
tem in the nucleus, there was interest in determining where they
went in terms of promoters and whether they were associated
with each other for some coordinate nuclear function. Therefore,
ChIP-qPCR assays were performed to determine if the type I IFN
players were specifically recruited to the promoter region of a gene
activated by IFNα in cells (17). The promoter region of the OAS1
gene, which has an IFN sensitive response element (ISRE) and is
involved in IFN antiviral activity,was thus examined (17). IFNAR1,
IFNAR2,TYK2,pSTAT1,and H3pY41 were found at the OAS1 pro-
moter, but not at the β-actin promoter, a gene that is not directly
affected by type I IFNs. Consistent with the ChIP data, immuno-
precipitation of IFNAR1 in nuclear extracts of IFNα treated cells,
followed by Western blotting showed TYK2, pSTAT1, and H3pY41
associated with IFNAR1. Thus, the various players in type I IFN
signaling were found associated in the nucleus of IFN treated cells
specifically at the promoter of a key gene in IFN antiviral activity.
Given the specific epigenetic events that are associated with
gene activation, ChIP analysis was used to monitor demethyla-
tion/acetylation of lysine 9 on histone H3 (17). Type I IFN treated
cells showed decreased trimethylated lysine on H3, H3K9me3, in
the OAS1 promoter region of cells. Acetylation of H3K9, H3K9ac,
occurred concomitantly over the same time span. Demethyla-
tion/acetylation of H3K9 is associated with gene activation (44,
45). Related to this, phosphorylation of H3 at Y41, H3pY41,
increased as H3K9me3 decreased over the same time period. By
comparison, the constitutively activated β-actin gene, which is not
affected by IFN, showed constitutive H3K9ac, no H3pY41, and
no H3K9me3. The nuclear trafficking and activities at specific
genes that are associated with treatment of cells with IFN suggest
that the receptor/transcription factor/JAK complex plays a key role
in specific gene activation, including the related heterochromatin
modifications.
FROM NON-CANONICAL SIGNALING TO IFN MIMETIC
DEVELOPMENT
Attachment of the fatty acid palmitic acid (lipo-) to the IFNγ pep-
tides for cell penetration conveyed IFN signaling properties (46).
Lipo-mIFNγ(95–132) and lipo-hIFNγ(95–134) possess classical
polycationic NLSs in their C-terminus and an alpha helix in their
N-terminus that were required for their mimetic activity (46, 47).
The mimetics activated STAT1α and induced its translocation to
the nucleus (48), and also possessed transactivational activity at
the GAS promoter, demonstrating that they functioned similar to
IFNγ in the nucleus (15). The mimetics possessed potent antiviral
activity against vesicular stomatitis virus (VSV) and encephalomy-
ocarditis virus (EMCV), and like IFNγ they induced increased
expression of MHC class II antigens on macrophages (18). The
induction of antiviral activity was confirmed by others (49).
A stringent test of the mimetic in terms of antiviral activity
was observed with a poxvirus, vaccinia virus, which is used world-
wide to vaccinate against smallpox infections, and is a prototype
of the poxvirus family (50). These viruses are particularly effective
in neutralizing host innate antiviral defense mechanisms, such as
the IFN system, because they produce soluble secreted proteins
that bind to and prevent IFNα, IFNβ, and IFNγ from binding to
their respective receptors on the cell membrane (50). An impor-
tant virulence factor of vaccinia virus is the B8R protein, which
is a homolog of the extracellular domain of the IFNγ receptor
and can therefore bind to intact IFNγ and prevent its interaction
with the receptor (51). It was hypothesized that the IFNγmimetics
would bypass the poxvirus virulence factor B8R protein that binds
to intact IFNγ, thus preventing its interaction with the receptor.
Human and murine IFNγ mimetic peptides were introduced into
an adenoviral vector for intracellular expression. Murine IFNγ
mimetic peptide, lipo-mIFNγ(95–132), was also expressed via
chemical synthesis with attached palmitic acid for penetration of
cell plasma membrane. In contrast to the intact human IFNγ, the
mimetics did not bind poxvirus B8R protein. Expression of B8R
protein in epithelial WISH cells did not block the antiviral effect
of the mimetics against EMCV or VSV, while the antiviral activ-
ity of human IFNγ was neutralized. Consistent with the antiviral
activity, the upregulation of MHC class I molecules on WISH cells
by the IFNγmimetics was not affected by B8R protein, while IFNγ
induced upregulation was blocked. Finally, the mimetics, but not
IFNγ, inhibited vaccinia virus replication in African green mon-
key kidney BSC-40 cells. The small peptide mimetics of IFNγ can
avoid the B8R virulence factor for poxviruses and thus are potential
candidates for antivirals against smallpox virus (43, 46, 48).
It was further shown that lipo-mIFNγ(95–132) protected
C57BL/6 mice against overwhelming lethal vaccinia virus infection
(48). Control mice died at 9–10 days post infection, but intraperi-
toneal injection of the mimetic as late as 6 days post infection
resulted in 40 percent protection. Administration of mimetic by
the oral route also completely protected mice against the intranasal
route of a lethal dose of vaccinia virus challenge. In addition to the
direct antiviral effects, the mimetic also possessed adjuvant effects
in boosting humoral and cellular immunity. This combination of
antiviral and adjuvant effects by the IFN mimetic probably played
a role in its potent anti-vaccinia virus properties. IFNγ is generally
not extensively used as a therapeutic, the reason for which is not
well understood. It should be noted that the presence of receptors
on a large number of cells could serve as a “sink,” thus affect-
ing access of IFNγ to sites and cells for which it was intended. The
IFNγmimetics do not recognize the receptor extracellular domain
and thus could possibly have better access to intended targets.
The pattern of nuclear signaling by type I IFNs is similar to
that of IFNγ nuclear signaling (11). Thus, in order to deter-
mine if IFNα1 and IFNβ possessed similar C-terminus function
intracellularly while losing extracellular function, truncated IFNs
IFNα1(69–189)R9 and IFNβ(100–187)R9 with nine arginines
(R9) for cell penetration were expressed in a bacterial system
and purified. As controls, these truncations were also expressed
without R9. Both IFNα1(69–189)R9 and IFNβ(100–187)R9
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possessed antiviral activity against EMCV, while the same con-
structs without R9 for cell penetration lacked antiviral activity. R9
alone also lacked antiviral activity. This is consistent with previous
studies that showed that intracellularly expressed IFNα possessed
antiproliferative and antiviral activity (38). The truncation studies,
however, are not subject to the argument that somehow the intra-
cellular IFN may have leaked out of the cell and interacted with
the extracellular receptor domains, since the truncations were not
functional in terms of extracellular induced antiviral activity.
There are over 20 different isoforms of type I IFNs and they
all function through the same heterodimeric receptor complex
(21, 52, 53). In addition to their similar antiviral activities, these
IFNs vary with respect to anticellular and cytotoxic (apoptotic)
effects. In this regard, IFNβ is the treatment of choice for relaps-
ing/remitting multiple sclerosis (MS) (14, 54). Further, it has been
shown that higher doses of IFNβ result in better therapeutic effi-
cacy (55), but undesirable toxic side-effects of flu-like symptoms,
liver damage, and bone marrow suppression limit the dose (56).
Differences in type I IFN toxicity (apoptosis) by different IFNs
were shown to be due to differential extracellular IFN receptor
recognition, where greater receptor occupancy due to higher bind-
ing affinity contributed to the toxic effects (13). This observation
has been confirmed by others (57).
For toxicity studies, mice were injected intraperitoneally on
alternate days with IFNβ, IFNβ(100–179)R9, or IFNα1(69–
189)R9, all of the same antiviral activity (2,000 units) (17).
Injection of mice with IFNβ resulted in approximately 15%
weight loss by day 10, while mice injected with the IFN mimetics
gained weight, which is expected under normal growth conditions
(Figure 3A) (17). A similar pattern of bone marrow suppression
occurred as reflected by peripheral lymphocyte count. IFNβ was
also pro-apoptotic, while the mimetics did not induce apoptosis.
Thus, under conditions of the same antiviral activity, IFNβ was
toxic and the type I IFN mimetics lacked symptoms associated with
toxicity such as weight loss, lymphopenia, and cellular toxicity.
IFNα1(69–189)R9 was tested for its ability to therapeutically
treat SJL/J mice for experimental allergic encephalomyelitis (EAE),
a mouse model of MS, without the toxicity associated with IFNβ
treatment. EAE replicates the symptoms of MS in humans, and is
induced by immunization of mice with various forms of myelin
components (58). It is thought that T cells play a key role in the
initiation and perpetuation of the inflammation that is associated
with EAE, and that microglia and macrophages are attracted to
the sites of inflammation by cytokines that are released by the
T cells (58). The knowledge of the specific cell types that are
involved in the inflammatory processes of EAE and MS has led
to the focus on specific targets for drug development (59). The
hallmark of treatment has until recently been IFNβ, but there are
undesirable side-effects such as flu-like symptoms and injection
site reactions (59). It is therefore important to develop new thera-
pies that are tolerable to patients and that act in a manner similar
to that of IFN.
Immunization of mice with bovine myelin basic protein where
cellular infiltration into the CNS has occurred by day 12 was
used to test the truncated IFNs (17). SJL/J mice were injected
intraperitoneally with saline, IFNα1(69–189)R9, or the control
peptide, IFNα1(69–189), 15µg each every other day starting from
FIGURE 3 |Type I IFN mimetics protect against EAE, but lack the
toxicity associated with the intact IFN. (A)Weight loss comparison.
Mice were injected i.p. with IFNβ (∆, 1000 U/mouse); IFNβ(100–179)R9
(©), 2000 U (200µg); or IFNα1(69–189)R9 (), 2000 U (200µg) on alternate
days. Activity refers to antiviral units (U). Note that IFNβ injected mice had a
greater than 15% loss of weight by day 11, while therapeutic mimetic
injected mice gained weight. (B) N-terminal truncated type I IFN mimetic,
IFNα1(69–189)R9, ameliorates EAE, a mouse model of MS. SJL/J mice
(n=5) were injected i.p. with PBS (•), IFNα1 mimetic IFNα1(69–189)R9 (N,
15µg/mouse), or mimetic absent cell-penetrating R9, IFNα1(69–189) (,
15µg/mouse) every other day starting from day 12 post-immunization of
mice with bovine myelin basic protein. Mean severity of disease was
graded as follows: 0, normal; 1, loss of tail tone; 2, hind leg weakness; 3,
paraparesis; 4, paraplegia; 5, moribund; and 6, death. See Ahmed et al. (17)
for details.
day 12 post-immunization with MBP. The IFNα mimetic with
the R9 reduced paralysis essentially completely, while the mice
treated with saline or the mimetic lacking R9 developed paraplegia
(Figure 3B) (17).
These mimetic results would suggest, as with binding studies
mentioned above, that it is the IFN signal at the receptor extracellu-
lar domain that is responsible for their toxic effects, while antiviral
and anti-EAE (MS) effects are associated with the intracellular
actions that are retained by the IFN mimetics without the associ-
ated toxicity. It is important to emphasize that the IFN mimetics
are products of the non-canonical model presented here.
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ENDOCYTOSIS AND NUCLEAR TRANSPORT OF IFNγ AND ITS
RECEPTOR: LEARNING FROM THE EGF RECEPTOR
Probably the most challenging conceptual aspect of the IFN signal-
ing described here is the movement of a protein such as IFNGR1
from the plasma membrane to the nucleus. The mechanism of
endocytosis of IFNGR1 and the relationship of this to the activa-
tion and nuclear translocation of STATαwas examined to deal with
this challenge (60). In untreated WISH cells, both receptor sub-
units IFNGR1 and IFNGR2 were constitutively localized within
caveolae-like microdomains isolated from the plasma membrane.
However, treatment of cells with IFNγ resulted in rapid migration
of IFNGR1 but not IFNGR2 from these microdomains. Filipin
treatment, which specifically inhibits endocytosis from caveolae-
like microdomains, inhibited the nuclear translocation of IFNγ
and IFNGR1 as well as the tyrosine phosphorylation and nuclear
translocation of STAT1α, but did not affect the binding of IFNγ
to WISH cells. In the Jurkat T lymphocyte cell line, which does
not express caveolin-1, nuclear translocation of IFNGR1 and
STAT1α were similarly inhibited by filipin pretreatment. Both
IFNGR1 and IFNGR2 were associated with lipid microdomains
in Jurkat cells, but only after stimulation with IFNγ, suggest-
ing that IFNGR subunits are recruited to lipid microdomains by
IFNγ binding in lymphocytes (Jurkat) in contrast to their consti-
tutive presence in epithelial (WISH) cells. Treatment of cells where
clathrin-dependent endocytosis is blocked did not inhibit either
the activation or nuclear translocation of STAT1α nor the nuclear
translocation of IFNγ and IFNGR1. Lipid microdomains were also
independently shown by others to play a key role in IFNγ receptor
endocytosis (61).
In another study of type I and type II IFN receptor endocyto-
sis, both IFNα and IFNγ receptors were shown to be internalized
by a classical clathrin-and dynamin-dependent endocytic pathway
(62). Lipid-based microdomains were also shown to play a role in
STAT activation and biological activity by IFNγ, but not by IFNα.
Overall, it appears that lipid microdomains play a key role in IFNγ
endocytosis and signaling, but this may not be the case for type
I IFNs.
Epidermal growth factor receptor (EGFR) is a transmembrane
glycoprotein that possesses intrinsic or receptor tyrosine kinase
activity (63, 64). This differs significantly from IFNγ receptor,
which has receptor-associated tyrosine kinase activity via JAK1
and JAK2. There are, however, similarities between the two recep-
tors in that both EGFR and IFNGR1 undergo nuclear translocation
following interaction with ligand. Both EGFR and IFNGR1 also
function as transcription/co-transcription factors at promoters of
genes that they activate and both have co-factors associated with
them in the nucleus, analogous to steroid/steroid receptor (SR)
signaling (11, 15, 65).
Considerable insight has been gained concerning the retrograde
trafficking of EGFR from the cell membrane into the nucleus.
Specifically, this system has been particularly useful in providing
insight into how a plasma membrane protein with a hydropho-
bic transmembrane sequence migrates through the nuclear pore
complex and functions as a transcription/co-transcription factor
at promoters of activated genes. Upon treatment of MDA-MB-468
breast cancer cells with epidermal growth factor (EGF), confocal
immunofluorescence revealed that EGFR underwent retrograde
movement to the Golgi and the ER (endoplasmic reticulum) where
the N-terminus was within the lumen of the Golgi/ER and the
C-terminus was exposed to the cytoplasm (66). Retrograde traf-
ficking was blocked by brefeldin A or dominant negative mutants
of the small GTPase ARF (ADP-ribosylation factor), of which both
treatments resulted in disassembly of the COPI (coat protein com-
plex I) to the Golgi. It was concluded that the COPI regulated
retrograde vesicular trafficking of EGFR from the Golgi to the ER.
It was further shown that treatment of MDA-MB-468 cells with
EGF resulted in trafficking of biotinylated cell-surface EGFR from
the ER to the INM (inner nuclear membrane) through the nuclear
pore complex, while maintaining its membrane-bound state (66,
67). It was confirmed that membrane-associated importin β reg-
ulated EGFR nuclear transport to the INM as well as to the
nucleus/nucleoplasm. EGF was associated with EGFR through the
retrograde transport pathway. Perhaps the most novel aspect of
this study was the demonstration that Sec61β was found to be
present in the INM and to associate with EGFR. Sec61β is a well-
known ER-associated translocon that has previously been shown
to be required for EGFR nuclear translocation (2). Translocons
are conserved protein-conducting channels in eukaryotes. Knock-
down of Sec61β expression reduced the level of EGFR in the nucle-
oplasm portion with concomitant accumulation in the INM (63,
67). Thus the Sec61β translocon played an unexpected critical role
in the release of membrane-anchored EGFR from the lipid bilayer
of the INM to the nucleus. These findings provide insight into
the mechanism of nuclear transport of a membrane-bound full-
length protein that functions as a transcription/co-transcription
factor.
Fibroblast growth factor (FGF) and its receptor (FGFR) have
previously been reviewed in detail concerning early studies of
nuclear events (68–70). FGF and FGFR can provide further insight
into nuclear transport mechanisms in terms of possible differ-
ences from EGFR in endocytic events. Briefly, FGFs are a family of
approximately 20 different growth factors and/or isoforms. They
interact at the cell-surface with FGF receptor tyrosine kinase, of
which there are at least four different genes. Like EGF/EGFR, both
FGF and FGFR undergo nuclear translocation in cells treated with
FGF. It has been shown that FGF1 but not FGFR1 possessed a
polycationic NLS, 21NYKKPKL (71). Endocytosis results in the
exposure of the cytoplasmic domain of FGFR1 to the cytosol,
while the N-terminus with associated FGF1 is in the endosomal
lumen. It has been shown that FGF1 can penetrate the mem-
brane of the endosomal vesicle to reach the cytoplasm (70). If
the FGF1/FGFR1 complex undergoes nuclear translocation via
the FGF1 NLS, the FGF1 would have to bind either to the recep-
tor cytoplasmic domain or to another molecule that also binds
FGFR1. For FGF1 translocation from the exogenous FGFR1 bind-
ing site to the cytosol and the nucleus, the C-terminal tail of the
cytoplasmic domain of FGFR1 was required (72). This constituted
approximately 50 amino acids downstream of the kinase domain
of FGFR1. This finding is similar to that for the IFNγ binding site
on the IFNGR1 cytoplasmic domain (42). Thus, it is tempting to
interpret this as evidence of a cytoplasmic binding site on FGFR1
for FGF1.
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Recent studies have provided more insight into how FGF1
and FGFR1 undergo nuclear translocation via a focus on FGF1.
Leucine-rich repeat containing 59 (LRRC59) was identified as an
intracellular binding partner of FGF1 (73). Following transloca-
tion of FGF1 across the endosomal membrane into the cytosol,
it was shown to bind to LRRC59 on the cytosolic side of the ER
membrane, which is crucial to FGF1 nuclear import. In this study,
it was shown that the NLS of LRRC59 mediates the interaction
with nuclear importins α and β, which are responsible for the
import of proteins into the nucleus via binding to the NLS. It was
proposed that this complex is transported along the continuous
membranes of the ER, outer nuclear membrane (ONM), nuclear
pore membrane, and the INM. Since FGFR1 is required for FGF1
nuclear import it would suggest that FGFR1 is part of this com-
plex, but FGFR1 was not followed in this study. Other studies have
suggested that importin β but not importin α is involved in the
nuclear translocation of FGFR1 (64).
Consistent with the above studies, FGFR1 has been shown not
to use the retrograde pathway of EGFR for nuclear import (64, 73).
Membrane-associated importin β was involved in EGFR nuclear
import, while cytosolic importins were required for FGFR. How-
ever, unlike the suggested scenario for FGF1 above, the comparison
of FGFR1 to EGFR indicated that FGFR1 does not bind to the INM
as determined by confocal microscopy (64). Thus, more details
must be worked out with FGFR1 movement from the plasma
membrane to the nucleus in a non-retrograde pathway that may
or may not be linked to that of FGF1 nuclear import. Thus, test-
ing for FGFR1 at the FGF1/LRRC59 complex would help provide
more insight to FGFR1 transport to the nucleus in the context of
FGF1 transport.
STEROID SIGNALING: THE TEMPLATE FOR NON-CANONICAL
IFNγ SIGNALING
In a search for a precedent, it seems that IFNγ, and proba-
bly EGF and FGF have similarities to that of SR signaling. We
now provide an overview of steroid hormone (SH)/SR signal-
ing to point out these similarities. SRs are a major subset of
nuclear receptors. Basically, synthesis of SHs occurs in the adrenal
cortex and in gonads (74). SHs are derivatives of cholesterol
that are biosynthesized through various biochemical pathways.
This involves the conversion of cholesterol into pregnenolone,
which is subsequently converted into 17-hydroxypregnenolone
and progesterone. 17-Hydroxypregnenolone gives rise to testos-
terone, which can be converted into estradiol via reduction. By a
series of specific hydroxylations, progesterone gives rise to cortisol
and aldosterone.
Broadly, the current model of SH signaling is as follows and is
summarized in Figure 4. SH binds to SRs located in the cytoplasm
or nucleus of the cell. In the absence of hormone, SR monomers
are associated with heat shock proteins (HSPs) and usually possess
some basal level of phosphorylation. Upon binding of hormone,
SRs dissociate from HSPs, dimerize and translocate to the nucleus
where they bind to HREs (hormone-response elements) at genes
that are activated by SHs. The complex of SH/SR recruits a series
of co-activator complexes to both regulate target gene transcrip-
tion as well as the associated epigenetic events that accompany
such activation. Site-specific phosphorylation of receptors occurs
FIGURE 4 | General overview of steroid signaling. (1) Ligand binds to the
receptor in the cytosol. (2)The receptor functions as a transcription/
co-transcription factor. (3) Co-activators such as kinases are associated with
the ligand/receptor complex, which translocates to the nucleus. (4) The
complex binds to response elements at specific genes. (5) Some of the
co-factors of the complex, such as tyrosine and non-tyrosine kinases, are
involved in the specific epigenetic events that accompany specific gene
activation. HRE, hormone-response element; MNAR, modulator of
non-genomic action of estrogen receptor; P, phosphotyrosine and
non-phosphotyrosine kinase activity by co-factors and kinases.
subsequently to hormone binding with varied kinetics, depending
on the kinase and the target in the receptor complex.
The kinases, although not the only components of the receptor-
associated co-activator complexes, are important for their action
on members of the complex, as well as for specific epigenetic events
of gene activation and thus act on histones as well as on members
of the receptor complex. Many of the SH phosphorylation sites
contain serine/threonine/proline motifs involving proline-specific
kinases, such as the cyclin-dependent kinases and MAPKs (75–77).
Tyrosine kinases such as Src have also been shown to participate in
SR signaling in the nucleus. SRs similarly cross-talk with receptor
tyrosine kinases such as EGFR. EGFR family members are impor-
tant targets in some of the most prevalent and difficult cancers,
such as non-small cell lung carcinoma (78, 79).
In addition to their presence in the cytoplasm, a subset of SRs is
also membrane-associated through an S-palmitoylation linkage to
the inner side of the plasma membrane (76, 80). The membrane-
associated SR may be in some cases the same as cytoplasmic SR,
but this is not universally agreed upon. Membrane SR is involved
in activation of MAPK and PI3K/Akt kinases.
In addition to the kinase-type activators described above,
there are also so-called primary SRCs (SR co-activators), of
which three are the most prominent (74). SRC proteins are
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recruited to hormone-bound SRs and bind through their LXXL
motifs. SRCs recruit secondary co-activators, such as the his-
tone acetyltransferase p300/CBP, the histone methyltransferases
PRMT1 (protein arginine N -methyltransferase 1) and CARM1
(co-activator-associated arginine methyltransferase 1), and the
chromatin remodeling complex SWI/SNF. These secondary co-
activators modify the chromatin and bridge the SR complex with
the general transcription machinery. Although the various kinases
are present, just how they associate with SR and SRCs is not pre-
cisely known. One does come up with, however, the general picture
of SH/SR-co-activator complexes where the co-activators may be
grouped as primary as the case for the SRCs or secondary as the
case for the histone transferases. If one were to restrict primary
co-activators to the SRCs, then the kinases could also possibly be
called secondary co-activators.
A comparison of IFNγ signaling in Figure 1B and SH signaling
in Figure 4 suggests the following similar features. Ligand asso-
ciates with the receptor intracellularly. In the case of IFNγ, first
there is extracellular binding to IFNGR1 and then intracellular
binding in conjunction with the endocytosis. SH penetrates the
plasma membrane and binds the cytoplasmic SR. In both cases
the receptors function as transcription/co-transcription factors.
Co-activators are associated with the ligand/receptor complex. An
overview of similarities between IFNGR1, IFNAR, EGFR, FGFR,
and SR systems is presented in Table 1. Currently, much more is
known concerning the SH/SR complex than the IFNγ/IFNGR1
or type I IFN/IFNAR complexes, but STATs and JAKs are asso-
ciated in the cytoplasm and the nucleus. In both cases, the
ligand-receptor-co-activator complex binds to response elements
of genes that are specifically activated. Some of the co-factors,
such as the kinases, are involved in specific epigenetic events
for both systems. We do not feel that IFNs are a special case
with respect to protein ligands with associated tyrosine kinase
activity or with receptor tyrosine kinases, as EGFR and FGFR
have similarities to the IFNs in receptor involvement in nuclear
aspects of gene activation. We further feel that all of the cytokines,
hormones, and growth factors that use the JAK/STAT pathway
are likely to also share these similarities. In our view the tem-
plate for all of this resides in the SH/SR system of specific gene
activation.
CONCLUSION
Our current understanding of cytokine signaling focuses in partic-
ular on the JAK/STAT pathway where activated STATs are responsi-
ble for specific gene activation even in the case of functionally dif-
ferent cytokines using the same STAT transcription factors. More
Table 1 | Receptors as coordinators of complex formation and function in genetic and epigenetic changes in gene activation.
Component Signaling systems
IFNγ IFNα EGF FGF SH
Ligand IFNγ IFNα, β, ε, ω, k, or τ EGF, TGFα FGF SH
• Activates receptor • Activates receptor • Activate receptor • Activates receptor • Activates receptor
• Provides NLS (40, 41) • Provides NLS (17, 11) • Provides NLS
Receptor IFNGR1 IFNAR1 IFNAR2 EGFR FGFR1, FGFR2 SR
•TF/Co-TF (15) IFNGR2 •Translocate to nucleus (17, 11) •TF/Co-TF •TF/Co-TF •TF/Co-TF








JAKs • STAT activation • STAT activation • STAT activation • STAT activation
• Epigenetic modification (16) • Epigenetic modification (17) • Epigenetic • Epigenetic
STATs STAT1α STATs 1 and 2 STATs 1, 3, 5 STAT5 STAT5
•TF in activated state (16) •TF in activated state (82) •TFs •TFs •TF for Progesterone










MAP kinase SRC 1, 2,
3 (75), Msk1 and Erk
(75)
In IFNγ, EGF, FGF, and SR systems similarities in terms of steps involved in specific gene activation are indicated. Erk, Extracellular receptor kinase; Co-TF, Co-
transcription factor; MAP Kinase, Mitogen activated protein kinase; Msk1, Mitogen, and stress activated kinase 1; Rsk1, Ribosomal S6 kinase 1; SH, steroid hormone;
SR, steroid receptor; Src, cytoplasmic tyrosine kinase; SRC, steroid receptor co-activators; TF, transcription factor; TK, tyrosine kinase. Detailed references for the
other players are provided in the text.
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recently, activated JAKs have been shown to perform important
epigenetic functions, but such functions have not been coordi-
nately coupled to the STAT transcription factors. It is possible that
some of the observed differences are due to the use of different cell
types and tissues by the studies referenced in this review. In the
presence of this void, we have developed a non-canonical model of
IFN signaling that takes the above events into account. This model
bears some similarity to SH/SR signaling and has been useful in
the development of IFN mimetics. It is our view that the model
can be readily tested in the context of the various genetic and epi-
genetic aspects of cytokine signaling where linkage of genetic and
epigenetic events is sought.
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